CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE
APC 和 TP53 作为西妥昔单抗反应生物标志物的临床验证
基本信息
- 批准号:10789666
- 负责人:
- 金额:$ 30.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:APC geneAgeAllelesBRAF geneBiological AssayBiological MarkersCancer and Leukemia Group BCaringCell LineCetuximabClinicClinicalCodeColorectal CancerConsensus SequenceDNA sequencingDataDrug UtilizationEngineeringEnsureEnvironmentEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorExclusionFDA approvedFormalinFreezingFundingGene Expression ProfileGene FrequencyGenesGenotypeHumanIn VitroKRAS2 geneKnowledgeLaboratoriesLeftLesionMeasuresModelingMolecularMutateMutationMutation DetectionNegative FindingObservational StudyOncogenesOutcomeParaffin EmbeddingPatient RecruitmentsPatient SelectionPatientsPerformancePharmacologic SubstancePhasePublishingRas/RafReportingReproducibilityResearch PersonnelResistanceRoleSamplingSideSpecificityTP53 geneTestingThe Cancer Genome AtlasTherapeuticTissue SampleTranslatingTreatment outcomeTumor Suppressor GenesValidationWorkagedcancer geneticsclinical practiceclinical trial recruitmentcohortcolon cancer patientscolorectal cancer treatmentcost effectiveexperiencegenetic predictorsimprovedindexinginhibitor therapymetastatic colorectalmutantpanitumumabprognosticresponsetherapeutic targettumortumor heterogeneity
项目摘要
PROJECT SUMMARY/ABSTRACT
The objective of this combined UH2/UH3 application is to develop a cost-effective, rapid, test that can be
rapidly translated to the clinic and ultimately be used to re-purpose a class of FDA-approved colorectal
cancer (CRC) EGFR inhibitor (EGFRi) therapeutics (cetuximab and panitumumab). To date, only negative
genetic predictors (mutant KRAS/NRAS) of EGFRi response have been employed clinically, currently
restricting EGFRi use to wild-type RAS/RAF subpopulations, and more recently, just to “left-sided” lesions.
We recently reported a new prognostic role for APC that relates to the number of alleles mutated and to the
association with other mutant genes such as KRAS and TP53 (Nat Commun, 2016). Further analysis also
revealed that mutant APC (A) genotypes, in combination with mutant TP53 (P), are strongly correlated with a
gene expression signature measuring cetuximab sensitivity (CTX-S). These data led to the provocative
hypothesis that mutant APC + TP53 (AP) genotypes together---more so than either mutant gene alone (A_ /
_P), or wild-type AP (_ _)---may have a new role in positively-predicting EGFRi outcomes (Nat Commun,
Under Review, 2018). This hypothesis is based on 3 key observations we have recently made in our cohort
and in TCGA data:
(1) CTX-S scores are significantly higher in: AP > A_ / _P > _ _ tumors in both WT and MUT KRAS tumors;
(2) AP mutations are more frequent in Left (cetuximab-sensitive) > Right (cetuximab-resistant) CRC;
(3) AP mutations are almost non-existent in MSI tumors (highly cetuximab-resistant).
These findings have two potentially high-impact clinical implications: (1) they re-define the patient selection
strategy by further restricting EGFRi therapies to wild-type RAS/RAF patients harboring AP mutations, thereby
increasing response rates; (2) they could expand the therapeutic opportunity to treat a substantial number of
previously-excluded mutant KRAS/NRAS patients who have AP mutations in both left and right CRCs. If the
test for these mutations is developed and clinically validated, the utilization of these drugs could be expanded
to ~25% more patients, including more first-line patients. For the vast majority of CRC patients, AP
mutations are not assessed in current practice. Unlike KRAS/NRAS oncogenes, both A and P are tumor
suppressor genes that can have a multitude of inactivating mutations that must be detected. Thus, there is an
opportunity to change clinical practice and standards of care to ultimately improve CRC outcomes with a new
test.
In the LabCorp CAP/CLIA environment, we plan to develop a new highly sensitive, specific and cost-effective
targeted DNA-sequencing “assay” to detect mutations in the coding regions of the principal genes APC, TP53,
KRAS, BRAF, NRAS from formalin fixed paraffin embedded (FFPE) tissue samples.
In the UH2 Phase of this proposal, a new FFPE targeted DNA sequencing assay, with greater potential to
accurately detect mutations at low allelic frequencies, will be analytically validated with the following
approaches so that it can be offered in a CAP/CLIA laboratory for testing clinical samples:
(1) A variety of cell lines, both native and engineered, will be used to ensure analytic sensitivity, specificity, and
reproducibility.
(2) ~100 formalin fixed paraffin embedded (FFPE) samples of variable age, quality, tumor heterogeneity,
grade, and stage matched to the highest quality, “gold standard” fresh frozen (FF) samples from the same
originating tumor will be used to assess assay performance.
In the UH3 Phase, we plan to perform clinical validation of the test developed in the UH2 Phase to provide
evidence that the presence of AP mutations may predict EGFRi responses translating into improved clinical
outcomes. Here, we will demonstrate that assay of APC and TP53 genotypes along with those already
performed as SOC (KRAS/NRAS/BRAF) can be clinically validated (i.e. used to predict cetuximab
sensitivity/response) using human samples derived from:
(1) a retrospective CRC observational study relating CRC genetics to predicted cetuximab sensitivity.
(2) a historical NCI trial (CALGB 80203) where patients were treated with cetuximab but were not sequenced.
项目摘要/摘要
这种UH 2/UH 3组合应用的目的是开发一种具有成本效益的快速测试,
迅速转化为临床,并最终用于重新利用一类FDA批准的结直肠癌
癌症(CRC)EGFR抑制剂(EGFRi)治疗(西妥昔单抗和帕尼单抗)。迄今为止,只有负
EGFRi应答的遗传预测因子(突变型KRAS/NRAS)目前已在临床上使用
限制EGFRi用于野生型RAS/RAF亚群,最近仅用于“左侧”病变。
我们最近报道了APC的一个新的预后作用,它与突变等位基因的数量和
与其他突变基因如KRAS和TP 53相关(Nat Commun,2016)。进一步分析还
突变型APC(A)基因型与突变型TP 53(P)基因型的结合,与
测量西妥昔单抗敏感性的基因表达特征(CTX-S)。这些数据引发了
假设突变APC + TP 53(AP)基因型一起-比单独的突变基因(A_ /
_P)或野生型AP(_ _)--可能在阳性预测EGFRi结果中具有新的作用(Nat Commun,
2018年)。这一假设基于我们最近在队列中进行的3项关键观察
在TCGA数据中:
(1)CTX-S评分在WT和MUT KRAS肿瘤中均显著高于AP > A_ / _P > _ _肿瘤;
(2)AP突变在左(西妥昔单抗敏感)>右(西妥昔单抗耐药)CRC中更常见;
(3)AP突变在MSI肿瘤中几乎不存在(高度西妥昔单抗耐药)。
这些发现有两个潜在的高影响力的临床意义:(1)他们重新定义病人的选择
通过进一步将EGFRi疗法限制于携带AP突变的野生型RAS/RAF患者,
提高反应率;(2)它们可以扩大治疗机会,以治疗大量的
之前排除的突变型KRAS/NRAS患者,在左侧和右侧CRC中均存在AP突变。如果
这些突变的测试开发和临床验证,这些药物的使用可以扩大
增加约25%的患者,包括更多的一线患者。对于绝大多数CRC患者,AP
在目前的实践中没有评估突变。与KRAS/NRAS癌基因不同,A和P都是肿瘤基因。
抑制基因可能具有大量必须检测的失活突变。因此,
有机会改变临床实践和护理标准,最终改善CRC结果,
test.
在LabCorp CAP/CLIA环境中,我们计划开发一种新的高度敏感,特异性和成本效益高的
靶向DNA测序“测定法”检测主要基因APC,TP 53,
福尔马林固定石蜡包埋(FFPE)组织样本的KRAS、BRAF、NRAS。
在该提案的UH 2阶段,一种新的FFPE靶向DNA测序检测方法,具有更大的潜力,
准确检测低等位基因频率的突变,将通过以下方法进行分析验证
方法,以便可以在CAP/CLIA实验室中提供用于测试临床样品的方法:
(1)将使用各种天然和工程化的细胞系来确保分析灵敏度、特异性和特异性。
再现性
(2)约100份福尔马林固定石蜡包埋(FFPE)样本,年龄、质量、肿瘤异质性各不相同,
等级和阶段匹配的最高质量,“黄金标准”新鲜冷冻(FF)样品来自相同的
起源肿瘤将用于评估测定性能。
在UH 3阶段,我们计划对UH 2阶段开发的测试进行临床确认,以提供
证据表明AP突变的存在可以预测EGFRi反应转化为改善的临床
结果。在这里,我们将证明APC和TP 53基因型的测定沿着那些已经被证实的基因型。
作为SOC(KRAS/NRAS/BRAF)进行,可进行临床验证(即用于预测西妥昔单抗
灵敏度/响应),使用源自以下的人样品:
(1)一项回顾性CRC观察性研究,将CRC遗传学与预测的西妥昔单抗敏感性联系起来。
(2)一项历史性NCI试验(CALGB 80203),患者接受西妥昔单抗治疗,但未进行测序。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes.
- DOI:10.3390/cancers13215394
- 发表时间:2021-10-27
- 期刊:
- 影响因子:5.2
- 作者:Thota R;Yang M;Pflieger L;Schell MJ;Rajan M;Davis TB;Wang H;Presson A;Pledger WJ;Yeatman TJ
- 通讯作者:Yeatman TJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY J YEATMAN其他文献
TIMOTHY J YEATMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY J YEATMAN', 18)}}的其他基金
APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity
APC TP53 组合突变作为预测 EGFRI 敏感性的生物标志物
- 批准号:
10610600 - 财政年份:2022
- 资助金额:
$ 30.94万 - 项目类别:
Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies
结直肠癌适应性突变的检测可能证明靶向治疗和免疫治疗相结合的合理性
- 批准号:
10289627 - 财政年份:2021
- 资助金额:
$ 30.94万 - 项目类别:
Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies
结直肠癌适应性突变的检测可能证明靶向治疗和免疫治疗相结合的合理性
- 批准号:
10613171 - 财政年份:2021
- 资助金额:
$ 30.94万 - 项目类别:
APC + TP53 Combinatorial Mutations Emerging as Biomarkers to Predict EGFRI Sensitivity
APC TP53 组合突变作为预测 EGFRI 敏感性的生物标志物
- 批准号:
10289625 - 财政年份:2021
- 资助金额:
$ 30.94万 - 项目类别:
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE
APC 和 TP53 作为西妥昔单抗反应生物标志物的临床验证
- 批准号:
10373564 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
CLINCIAL VALIDATION OF APC AND TP53 AS BIOMARKERS FOR CETUXIMAB RESPONSE
APC 和 TP53 作为西妥昔单抗反应生物标志物的临床验证
- 批准号:
10381742 - 财政年份:2019
- 资助金额:
$ 30.94万 - 项目类别:
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE
利用混合 RNA 和 DNA 分子特征进行个体化结肠癌治疗
- 批准号:
8738408 - 财政年份:2012
- 资助金额:
$ 30.94万 - 项目类别:
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE
利用混合 RNA 和 DNA 分子特征进行个体化结肠癌治疗
- 批准号:
8547787 - 财政年份:2012
- 资助金额:
$ 30.94万 - 项目类别:
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE
利用混合 RNA 和 DNA 分子特征进行个体化结肠癌治疗
- 批准号:
9133794 - 财政年份:2012
- 资助金额:
$ 30.94万 - 项目类别:
INDIVIDUALIZING COLON CANCER THERAPY USING HYBRID RNA AND DNA MOLECULAR SIGNATURE
利用混合 RNA 和 DNA 分子特征进行个体化结肠癌治疗
- 批准号:
8918486 - 财政年份:2012
- 资助金额:
$ 30.94万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 30.94万 - 项目类别:
Research Grant